Nektar Therapeutics (NKTR) Total liabilities 2016–2025
Nektar Therapeutics (NKTR) total liabilities at each fiscal year-end, per SEC filings.
$190.6MFY2025 · since FY2016: $480.7M → $190.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $190.6M | -21.6% |
| FY2024 | $243.1M | -9.0% |
| FY2023 | $267.0M | -22.4% |
| FY2022 | $344.0M | -21.4% |
| FY2021 | $437.7M | -5.2% |
| FY2020 | $461.5M | -19.3% |
| FY2019 | $572.0M | +32.2% |
| FY2018 | $432.6M | +2.7% |
| FY2017 | $421.0M | -12.4% |
| FY2016 | $480.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NKTR financial trends
NKTR RevenueNKTR Net incomeNKTR Net marginNKTR Gross profitNKTR Gross marginNKTR Operating incomeNKTR Operating marginNKTR Operating cash flowNKTR Free cash flowNKTR Capital expendituresNKTR Return on equityNKTR Stock buybacksNKTR Dividends paidNKTR Total assetsNKTR Shareholders’ equityNKTR overview →